VahatiCor Advances U.S. Clinical Study for CMD with First Patient Enrollment

VahatiCor Enrolls the First U.S. Patient in SERRA-I Clinical Study

VahatiCor, Inc., a pioneering company in the medical technology sector, is making significant strides in combating coronary microvascular dysfunction (CMD) with the commencement of their SERRA-I clinical study. This study is crucial as it marks the enrollment of the first patient in the United States for the A-FLUX Reducer System®, a device designed to enhance blood flow within the heart's microvascular network.

A Significant Milestone

On June 17, 2026, VahatiCor announced the enrollment of this initial patient at Yale-New Haven Hospital, which is associated with Yale School of Medicine. The enrolled patient is being treated under the supervision of Dr. Samit Shah, an esteemed interventional cardiologist, who serves as one of the co-principal investigators for this important clinical study. This development signifies a pivotal moment in the SERRA-I study, as it aims to evaluate the efficacious application of the A-FLUX Reducer System in patients suffering from symptomatic CMD.

Understanding CMD

CMD is a condition that affects millions of individuals, leading to persistent symptoms such as angina and chest pain, despite the absence of significant blockages in the major coronary arteries. By harnessing the capabilities of the A-FLUX Reducer System®, VahatiCor aims to address the inefficacy of current treatment options, offering hope for the substantial number of patients lacking effective therapies targeted at CMD.

The A-FLUX Reducer System®

The A-FLUX Reducer System® features a self-expanding nitinol design that can be delivered to the coronary sinus via catheter. Its primary function is to directly influence blood flow through smaller vessels within the heart, addressing the challenges presented by microvascular dysfunction. This investigational device is currently not approved by the U.S. FDA for commercial use but represents a promising advancement in interventional cardiology.

A Commitment to Innovation

Harry D. Rowland, PhD, the Chief Executive Officer of VahatiCor, expressed his enthusiasm for this development, stating, “Treating our first U.S. patient brings the A-FLUX Reducer System into U.S. clinical investigation. Cardiology is moving toward treating microvascular disease as a frontline condition, and the A-FLUX Reducer System is built for this shift.” His sentiments reflect the growing consensus within the cardiology field about the necessity to treat microvascular disease more proactively.

Dr. Shah, also noted the importance of this patient enrollment, stating, “Patients with CMD are highly symptomatic and underserved by current therapies.” This perspective underscores the urgency and necessity for developing viable treatment alternatives that effectively target the complexities of CMD.

The Path Forward

As part of the broader SERRA clinical program, the SERRA-I study encompasses various centers across the United States and Europe, with ongoing efforts to increase patient enrollment. VahatiCor's commitment to addressing the realities of CMD through innovative solutions stands as a beacon of hope for many patients who have long awaited effective treatments.

Conclusion

The engagement of the first U.S. patient in the SERRA-I study marks just the beginning for VahatiCor and its revolutionary approach to treating CMD. The A-FLUX Reducer System® embodies the company’s dedication to advancing patient care by focusing on issues that have historically been overshadowed by more visible coronary artery diseases. As this clinical study progresses, the insights gained will hopefully pave the way for new standards of care in the management of CMD, ultimately improving the quality of life for millions affected by this condition.